The importance of applying toxicogenomics to increase the efficiency of drug discovery

Pharmacogenomics

Volumn 6, Issue 6, 2005, Pages 547-550

  Barros, Scott A ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

ACCESS TO INFORMATION; ACCURACY; BIOINFORMATICS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG INDUCED DISEASE; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; EDITORIAL; GENE EXPRESSION PROFILING; GENETIC DATABASE; GENOTOXICITY; GOOD LABORATORY PRACTICE; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; MATHEMATICAL MODEL; NONHUMAN; POLYMERASE CHAIN REACTION; POSTMARKETING SURVEILLANCE; QUANTITATIVE ANALYSIS; STANDARDIZATION; TOXICOGENETICS;

ANIMALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION PROFILING; GENOMICS; TOXICOGENETICS; TOXICOLOGY;

EID: 25144442331     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.6.6.547     Document Type: Editorial

References (12)

1. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711-715 (2004).
2. DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
3. DiMasi JA: The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 20(Suppl. 3), 1-10 (2002).
4. Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W, Ahr HJ: Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver. Mutat. Res. 575(1-2), 61-84 (2005).
5. Hamadeh HK, Bushel PR, Jayadev S et al.: Prediction of compound signature using high-density gene expression profiling. Toxicol. Sci. 67, 232-240 (2002).
6. Thukral SK, Nordone PJ, Hu R et al.: Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. Toxicol. Pathol. 33(3), 343-355 (2005).
7. Burczynski ME, McMillian M, Ciervo J et al.: Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol Sci. 58, 399-415 (2000).
8. Waring JF, Jolly RA, Ciurlionis R et al.: Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol. Appl. Pharmacol. 175, 28-42 (2001).
9. Sawada H, Takami K, Asahi S: A toxicogenomics approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 83(2), 282-292 (2005).
10. Hayes KR, Bradfield CA: Advances in toxicogenomics. Chem. Res. Toxicol. 18(3), 403-414 (2005).
11. Dambach DM, Andrews BA, Moulin F: New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol. Pathol. 33, 17-26 (2005).
12. Kaplowitz N: Idiosyncratic drug hepatotoxicity. Nature Rev. Drug Discov. 4, 489-499 (2005).